Y-mAbs Therapeutics (NASDAQ:YMAB) Releases Earnings Results, Misses Expectations By $0.08 EPS

Y-mAbs Therapeutics (NASDAQ:YMAB) posted its quarterly earnings results on Monday. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.08), Zacks reports. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. The business had revenue of $22.80 million during the quarter, compared to analysts’ expectations of $23.09 million. During the same quarter last year, the firm earned ($0.14) earnings per share. Y-mAbs Therapeutics updated its FY 2024 guidance to EPS.

Y-mAbs Therapeutics Trading Up 1.9 %

Shares of NASDAQ:YMAB opened at $12.20 on Thursday. Y-mAbs Therapeutics has a 1 year low of $4.69 and a 1 year high of $20.90. The business has a fifty day simple moving average of $11.84 and a 200 day simple moving average of $13.71. The firm has a market cap of $535.37 million, a price-to-earnings ratio of -24.43 and a beta of 0.66.

Insider Buying and Selling at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 7,351 shares of Y-mAbs Therapeutics stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total transaction of $95,563.00. Following the sale, the insider now directly owns 232,681 shares of the company’s stock, valued at $3,024,853. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, insider Thomas Gad sold 7,351 shares of the business’s stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $13.00, for a total value of $95,563.00. Following the transaction, the insider now directly owns 232,681 shares of the company’s stock, valued at approximately $3,024,853. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Bo Kruse sold 31,371 shares of the business’s stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $12.07, for a total value of $378,647.97. Following the completion of the transaction, the chief financial officer now directly owns 210,877 shares in the company, valued at $2,545,285.39. The disclosure for this sale can be found here. Insiders have sold a total of 99,444 shares of company stock worth $1,203,925 over the last three months. Corporate insiders own 21.50% of the company’s stock.

Analysts Set New Price Targets

YMAB has been the subject of a number of analyst reports. Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a report on Tuesday. BMO Capital Markets reduced their price target on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday. Canaccord Genuity Group reissued a “buy” rating and issued a $26.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday. Finally, Morgan Stanley cut their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a research note on Tuesday. Two equities research analysts have rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $19.29.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.